Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX).

Full DD Report for CPRX

You must become a subscriber to view this report.


Recent News from (NASDAQ: CPRX)

Catalyst Pharmaceuticals (CPRX) Presents At Rodman & Renshaw.C. Wainwright 20th Annual Global Investment Conference - Slideshow
The following slide deck was published by Catalyst Pharmaceuticals, Inc. in conjunction with this Read more ...
Source: SeekingAlpha
Date: September, 06 2018 14:54
Week 36 Breakout Forecast: Short-Term Picks To Give You An Edge
Breakout Forecast Selections for Week 36: Market conditions have generated a strong increase in positive breakout momentum and a decline negative momentum this week. The positive momentum gauge continues higher to 65 up from a value of 51 at the end of last week. The yellow positive mome...
Source: SeekingAlpha
Date: September, 01 2018 13:03
Catalyst Pharmaceuticals to Present at Rodman & Renshaw's 20th Annual Global Investment Conference
CORAL GABLES, Fla., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, toda...
Source: GlobeNewswire
Date: August, 29 2018 08:03
Catalyst Pharmaceuticals Appoints Dr. Stanley Iyadurai as Vice President of Clinical Development
CORAL GABLES, Fla., Aug. 20, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, toda...
Source: GlobeNewswire
Date: August, 20 2018 08:03
Catalyst Pharmaceuticals Inc (CPRX) CEO Patrick McEnany on Q2 2018 Results - Earnings Call Transcript
Catalyst Pharmaceuticals Inc (CPRX) Q2 2018 Earnings Conference Call August 08, 2018 08:30 AM ET Executives Alicia Grande - Chief Financial Officer Patrick McEnany - Chairman and Chief Executive Officer Steve Miller - Chief Operating Officer and Chief Scientific Officer Gary In...
Source: SeekingAlpha
Date: August, 08 2018 12:04
Catalyst Pharmaceuticals beats by $0.02
Catalyst Pharmaceuticals (NASDAQ: CPRX ): Q2 EPS of -$0.06 beats by $0.02 . Cash and cash equivalents of $9.88M Press Release More news on: Catalyst Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: August, 07 2018 16:36
Catalyst Pharmaceuticals Announces Second Quarter 2018 Financial Results and Provides Corporate Update
CORAL GABLES, Fla., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today reported f...
Source: GlobeNewswire
Date: August, 07 2018 16:19
Catalyst Pharmaceuticals expands commercial leadership team
Catalyst Pharmaceuticals (NASDAQ: CPRX ) has appointed Jason James as Senior Vice President of Commercial Operations & Analytics, Jeff Del Carmen as Senior Vice President of Sales and Marketing, Kevin Rohrbach as Senior Director of Patient Engagement/Advocacy, and Maria Pandolfo as Sen...
Source: SeekingAlpha
Date: August, 06 2018 08:16
Catalyst Pharmaceuticals Expands Commercial Leadership Team
CORAL GABLES, Fla., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, toda...
Source: GlobeNewswire
Date: August, 06 2018 08:03
Alexion: Finding Success By Improving Lives
When you're feeling like investing with your conscience, a company like Alexion Pharmaceuticals ( ALXN ) can give you that warm and fuzzy feeling. Alexion develops treatments for rare diseases where no other treatment is available. As a conscientious investor, you can feel great about how Al...
Source: SeekingAlpha
Date: August, 06 2018 02:01

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-132.522.472.542.37153,737,321
2018-12-122.502.402.542.391,559,017
2018-12-112.372.492.512.36051,505,417
2018-12-102.382.352.43992.30918,994
2018-12-072.222.362.4152.213,021,016

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-13635,6761,765,40636.0074Short
2018-12-12249,792426,31558.5933Short
2018-12-11207,495448,70646.2430Short
2018-12-10105,635290,77736.3285Short
2018-12-07740,3361,322,90255.9630Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CPRX.


About Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)

Logo for Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)

Not available

 

Contact Information

 

 

Current Management

  • Patrick McEnany / CEO
  • Alicia Grande / CFO

Current Share Structure

  • Market Cap: $345,614,273 - 05/15/2018
  • Issue and Outstanding: 102,556,164 - 03/09/2018

 


Recent Filings from (NASDAQ: CPRX)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 19 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 17 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 29 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018

 

 


Daily Technical Chart for (NASDAQ: CPRX)

Daily Technical Chart for (NASDAQ: CPRX)


Stay tuned for daily updates and more on (NASDAQ: CPRX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CPRX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CPRX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CPRX and does not buy, sell, or trade any shares of CPRX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/